REFERENCES
1. Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. JAMA. 2020;323:1061-69.
3. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-81.
4. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017-32.
5. Feldman EL, Savelieff MG, Hayek SS, Pennathur S, Kretzler M, Pop-Busui R. COVID-19 and diabetes: a collision and collusion of two diseases. Diabetes. 2020;69:2549-65.
6. Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69:2048-53.
7. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626-31.
8. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593-607.
9. Wu J, Zhang J, Sun X, et al. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. Diabetes Obes Metab. 2020;22:1907-14.
10. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol. 2021;58:139-44.
11. Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1068-1077.e3.
12. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813-22.
13. Zhang Y, Li H, Zhang J, et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: a single-centre, retrospective, observational study in Wuhan. Diabetes Obes Metab. 2020;22:1443-54.
14. Gupta R, Misra A. Clinical considerations in patients with diabetes during times of COVID19: an update on lifestyle factors and antihyperglycemic drugs with focus on India. Diabetes Metab Syndr. 2020;14:1777-81.
15. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
16. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-42.
17. Shenoy A, Ismaily M, Bajaj M. Diabetes and covid-19: a global health challenge. BMJ Open Diabetes Res Care. 2020;8:e001450.
18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
19. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30:1236-48.
20. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135-49.
21. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18.
22. WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Last accessed on 30 Mar 2023].
23. Ayoubkhani DP, Gaughan C. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021 [Last accessed on 30 Mar 2023].
24. Tenforde MW, Devine OJ, Reese HE, et al. Point prevalence estimates of activity-limiting long-term symptoms among U.S. adults ≥1 month after reported SARS-CoV-2 infection, November 1, 2021. J Infect Dis. 2022; doi: 10.1093/infdis/jiac281.
25. Sisó-Almirall A, Brito-Zerón P, Conangla Ferrín L, et al. Long covid-19: proposed primary care clinical guidelines for diagnosis and disease management. Int J Environ Res Public Health. 2021;18:4350.
26. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. a systematic review of the current data. Front Med (Lausanne). 2021;8:653516.
27. Munblit D, Nicholson T, Akrami A, et al. PC-COS project steering committee. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10:715-24.
28. Roth A, Chan PS, Jonas W. Addressing the long COVID Crisis: integrative health and long COVID. Glob Adv Health Med. 2021;10:21649561211056597.
29. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.
30. Mittal J, Ghosh A, Bhatt SP, Anoop S, Ansari IA, Misra A. High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: a case-control study. Diabetes Metab Syndr. 2021;15:102302.
31. Jayasinghe S, Misra A, Hills AP. Post-COVID-19 syndrome and type 2 diabetes: primacy of exercise in prevention and management. Diabetes Metab Syndr. 2022;16:102379.
32. Sosale A, Sosale B, Kesavadev J, et al. Steroid use during COVID-19 infection and hyperglycemia - What a physician should know. Diabetes Metab Syndr. 2021;15:102167.
33. Mechi A, Al-Khalidi A, Al-Darraji R, et al. Long-term persistent symptoms of COVID-19 infection in patients with diabetes mellitus. Int J Diabetes Dev Ctries. 2022;42:49-52.
34. Ceriello A, Standl E, Catrinoiu D, et al. Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. 2020;43:1427-32.
35. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194:105921.
36. Raveendran AV, Misra A. Post COVID-19 Syndrome (“Long COVID”) and diabetes: challenges in diagnosis and management. Diabetes Metab Syndr. 2021;15:102235.
37. CDC. Long-term effects of COVID-19; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html [Last accessed on 30 Mar 2023].
38. Shin J, Toyoda S, Nishitani S, et al. Possible involvement of adipose tissue in patients with older age, obesity, and diabetes with SARS-CoV-2 infection (COVID-19) via GRP78 (BIP/HSPA5): significance of hyperinsulinemia management in COVID-19. Diabetes. 2021;70:2745-55.
39. Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022;18:75-6.
40. Liang L, Yang B, Jiang N, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020;35:e418.
41. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220-32.
42. Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52:575-81.
43. Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: a systematic review and meta-analysis. Prim Care Diabetes. 2022;16:591-3.
44. Simani L, Ramezani M, Darazam IA, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J Neurovirol. 2021;27:154-9.
45. Fernández-de-Las-Peñas C, Florencio LL, Gómez-Mayordomo V, Cuadrado ML, Palacios-Ceña D, Raveendran AV. Proposed integrative model for post-COVID symptoms. Diabetes Metab Syndr. 2021;15:102159.
46. Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19. Diabetes Care. 2020;43:2938-44.
47. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.
48. Estiri H, Strasser ZH, Brat GA, Semenov YR, Patel CJ, Murphy SN. Consortium for Characterization of COVID-19 by EHR (4CE). Evolving phenotypes of non-hospitalized patients that indicate long Covid. medRxiv. ;2021:2021.
49. Yaksi N, Teker AG, Imre A. Long COVID in hospitalized COVID-19 patients: A Retrospective Cohort Study. Iran J Public Health. 2022;51:88-95.
50. Steenblock C, Hassanein M, Khan EG, et al. Diabetes and COVID-19: short- and long-term consequences. Horm Metab Res. 2022;54:503-9.
51. Thompson EJ, Williams DM, Walker AJ, et al. OpenSAFELY Collaborative. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.
52. Cariou B, Hadjadj S, Wargny M, et al. CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500-15.
53. Bonyek-Silva I, Cerqueira-Silva T, Nunes S, et al. Prediabetes induces more severe acute COVID-19 associated with IL-6 production without worsening long-term symptoms. Front Endocrinol (Lausanne). 2022;13:896378.
54. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259-64.
55. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10:311-21.
56. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23:870-4.
57. Zhang J, Shu T, Zhu R, Yang F, Zhang B, Lai X. The long-term effect of COVID-19 disease severity on risk of diabetes incidence and the near 1-year follow-up outcomes among postdischarge patients in Wuhan. J Clin Med. 2022;11:3094.
58. Barrett CE, Koyama AK, Alvarez P, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:59-65.
59. The OpenSAFELY Collaborative, John Tazare, Alex J Walker, et al. Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform. medRxiv. Available from: https:// www.medrxiv.org/content/10.1101/2021.01.22.21250304v2 [Last accessed on 30 Mar 2023].
60. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.
61. Gentile S, Strollo F, Mambro A, Ceriello A. COVID-19, ketoacidosis and new-onset diabetes: Are there possible cause and effect relationships among them? Diabetes Obes Metab. 2020;22:2507-8.
62. Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. N Engl J Med. 2020;383:789-90.
63. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22:1897-906.
64. Zhou W, Ye S, Wang W, Li S, Hu Q. Clinical features of COVID-19 patients with diabetes and secondary hyperglycemia. J Diabetes Res. 2020;2020:3918723.
65. Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63:2102-11.
66. Yi H, Lu F, Jin X, et al. Clinical characteristics and outcomes of coronavirus disease 2019 infections among diabetics: a retrospective and multicenter study in China. J Diabetes. 2020;12:919-28.
67. Fadini GP, Morieri ML, Boscari F, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168:108374.
68. Lampasona V, Secchi M, Scavini M, et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020;63:2548-58.
69. Smith SM, Boppana A, Traupman JA, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J Med Virol. 2021;93:409-15.
70. Montori VM. Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19. Ann Intern Med. 2022;175:JC93.
71. Frere JJ, tenOever BR. Cardiometabolic syndrome - an emergent feature of Long COVID? Nat Rev Immunol. 2022;22:399-400.
72. Unsworth R, Wallace S, Oliver NS, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care. 2020;43:e170-1.
73. Vlad A, Serban V, Timar R, et al. Increased incidence of type 1 diabetes during the COVID-19 pandemic in romanian children. Medicina (Kaunas). 2021;57:973.
74. Tittel SR, Rosenbauer J, Kamrath C, et al. DPV Initiative. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care. 2020;43:e172-3.
75. Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 Pandemic in Germany: results from the DPV registry. Diabetes Care. 2022;45:1762-71.
76. Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of COVID-19: A metabolic perspective. Elife. 2022:11.
77. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17:11-30.
78. Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473-87.
79. Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495-506.e8.
80. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831-1833.e3.
81. Müller JA, Groß R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3:149-65.
82. Suwanwongse K, Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID-19: Causality or coincidence? J Med Virol. 2021;93:1150-3.
84. Montefusco L, Ben Nasr M, D'Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3:774-85.
85. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782-92.
86. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.
87. Zhang Y, Cui Y, Shen M, et al. medical team from Xiangya Hospital to support Hubei; China. Association of diabetes mellitus with disease severity and prognosis in COVID-19: a retrospective cohort study. Diabetes Res Clin Pract. 2020;165:108227.
88. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13:465-76.
89. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-15.
90. Prattichizzo F, De Nigris V, Spiga R, et al. Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res Rev. 2018;41:1-17.
91. Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021;33:1565-1576.e5.
92. Paneni F, Patrono C. Increased risk of incident diabetes in patients with long COVID. Eur Heart J. 2022;43:2094-5.
93. Bansal R, Gubbi S, Koch CA. COVID-19 and chronic fatigue syndrome: an endocrine perspective. J Clin Transl Endocrinol. 2022;27:100284.
94. Sathish T, Tapp RJ, Cooper ME, Zimmet P. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 2021;47:101204.
95. Fignani D, Licata G, Brusco N, et al. SARS-CoV-2 receptor angiotensin i-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature. Front Endocrinol (Lausanne). 2020;11:596898.
96. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193-9.
97. Coate KC, Cha J, Shrestha S, et al. HPAP Consortium. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metab. 2020;32:1028-1040.e4.
98. Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861-5.
99. Hayden MR. An Immediate and Long-Term Complication of COVID-19 may be type 2 diabetes mellitus: the central role of β-cell dysfunction, apoptosis and exploration of possible mechanisms. Cells. 2020;9:2475.
100. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15:629-34.
101. Russo B, Menduni M, Borboni P, Picconi F, Frontoni S. Autonomic nervous system in obesity and insulin-resistance-the complex interplay between leptin and central nervous system. Int J Mol Sci. 2021;22:5187.
102. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210-6.
103. McKeigue PM, McGurnaghan S, Blackbourn L, et al. Relation of incident type 1 diabetes to recent COVID-19 infection: cohort study using e-health record linkage in Scotland. Diabetes Care. ;2022:dc220385.
104. Alaqeel A, Aljuraibah F, Alsuhaibani M, et al. The impact of COVID-19 pandemic lockdown on the incidence of new-onset type 1 diabetes and ketoacidosis among saudi children. Front Endocrinol (Lausanne). 2021;12:669302.
105. Mameli C, Scaramuzza A, Macedoni M, et al. Type 1 diabetes onset in Lombardy region, Italy, during the COVID-19 pandemic: The double-wave occurrence. EClinicalMedicine. 2021;39:101067.
106. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9:e14726.
107. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-23.
108. Cheng Y, Shen P, Tao Y, et al. Reduced antibody response to COVID-19 vaccine composed of inactivated SARS-CoV-2 in diabetic individuals. Front Public Health. 2022;10:1025901.
109. Richard SA, Pollett SD, Fries AC, et al. Epidemiology; Immunology; and Clinical Characteristics of Emerging Infectious Diseases With Pandemic Potential (EPICC) COVID-19 Cohort Study Group. Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw Open. 2023;6:e2251360.
110. Chourasia P, Goyal L, Kansal D, et al. Risk of new-onset diabetes mellitus as a Post-COVID-19 condition and possible mechanisms: a scoping review. J Clin Med. 2023;12:1159.
